QT Prolongation Risk Calculator
Patient Risk Assessment
This tool helps identify patients at high risk for QT prolongation when prescribed macrolide antibiotics. Based on AHA guidelines and clinical studies, it assesses seven key risk factors.
Risk Assessment
Your patient's QT prolongation risk score:
Recommendations:
Macrolides are among the most commonly prescribed antibiotics in the U.S., used for everything from sinus infections to pneumonia. But for some patients, these drugs carry a hidden danger: a rare but deadly heart rhythm problem called Torsades de Pointes. It’s not common-but when it happens, it can be fatal. The risk isn’t the same for all macrolides, and it’s not the same for all patients. Knowing who’s at risk and why can save lives.
How Macrolides Affect the Heart
Macrolide antibiotics like azithromycin, clarithromycin, and erythromycin work by stopping bacteria from making proteins. But they also interact with a specific ion channel in heart cells called IKr, which controls how quickly the heart resets after each beat. When this channel gets blocked, the heart takes longer to repolarize. On an ECG, that shows up as a longer QT interval.
That delay might sound harmless, but it can trigger early afterdepolarizations-abnormal electrical spikes that set off chaotic heart rhythms. The most dangerous of these is Torsades de Pointes, a twisting pattern of ventricular tachycardia that can degenerate into cardiac arrest. It doesn’t happen often, but when it does, it often happens fast.
Research shows clarithromycin is the strongest blocker of IKr, followed by erythromycin. Azithromycin is weaker, but it’s still a player. A 2023 study in Frontiers in Cardiovascular Medicine confirmed this ranking: clarithromycin ≈ roxithromycin > erythromycin > azithromycin. That’s why clarithromycin shows up more often in adverse event reports-even though it’s prescribed less often.
The Real Risk: It’s Not the Drug, It’s the Patient
Most people who take azithromycin for a sore throat won’t have a problem. The baseline risk of TdP in healthy adults is less than 1 in 100,000. But add just one risk factor, and that number climbs.
The American Heart Association lists seven major risk factors:
- Female sex (2-3.5 times higher risk)
- Age over 65 (1.8 times higher risk)
- Structural heart disease (2.2 times higher risk)
- Low potassium or magnesium (3.1 times higher risk)
- Concurrent use of other QT-prolonging drugs (2.5-5 times higher risk)
- Kidney impairment (1.7 times higher risk)
- Genetic long QT syndrome (5-10 times higher risk)
Here’s the catch: most patients who end up with TdP have at least two of these. A 2021 case series in the Journal of Clinical Medicine found that 9 out of 12 patients with clarithromycin-induced TdP were taking another QT-prolonging drug-often a diuretic, antidepressant, or antifungal. Nearly all had low potassium. That’s not coincidence. That’s a perfect storm.
Comparing Macrolides: Clarithromycin vs. Azithromycin
There’s a lot of confusion around whether azithromycin is safer than clarithromycin. The answer is yes-but not by much, and only in low-risk people.
A 2012 study in the New England Journal of Medicine by Wayne Ray and colleagues found azithromycin was linked to a 2.88 times higher risk of cardiovascular death compared to amoxicillin. That caused a major stir. But later studies dug deeper. When researchers adjusted for 108 variables-including why the patient was prescribed the antibiotic in the first place-the difference vanished. The odds ratio dropped to 1.01. That suggests the real issue isn’t azithromycin itself, but that sicker patients get it more often.
Clarithromycin, on the other hand, consistently shows higher risk. A 2012 Danish study found clarithromycin was tied to a 77% higher risk of cardiac death than penicillin V. The FDA’s own adverse event database from 2010-2020 showed clarithromycin accounted for 58% of all macrolide-related QT events, even though it’s only used in about 15% of cases.
Why? Three reasons:
- It’s a stronger IKr blocker.
- It inhibits CYP3A4, which means it can raise levels of other QT-prolonging drugs (like statins or antiarrhythmics).
- It’s often prescribed to older patients with multiple meds and kidney issues.
Azithromycin doesn’t inhibit CYP3A4, so it’s less likely to cause drug interactions. But it still prolongs QT-just less. And when combined with other risk factors, even a small prolongation can be dangerous.
What About Other Antibiotics?
Not all antibiotics carry this risk. Doxycycline, amoxicillin, and cephalexin have no known QT effect. Fluoroquinolones like levofloxacin and moxifloxacin do-sometimes more than macrolides. Moxifloxacin can prolong QT by 15-20 ms, similar to clarithromycin.
But here’s the problem: doctors often pick macrolides because they’re good for atypical pneumonia, bronchitis, and sinus infections. They’re also less likely to cause diarrhea than fluoroquinolones. So even when the risk is known, there’s still a reason to use them.
The key isn’t avoiding macrolides entirely-it’s avoiding them in the wrong people.
How to Stay Safe: A Practical Guide
Doctors aren’t supposed to guess. There are tools to help.
The AHA recommends a three-step approach:
- Screen for the seven risk factors before prescribing. Check the ECG for baseline QTc. Men >450 ms, women >470 ms = high risk.
- Check electrolytes. Low potassium or magnesium? Fix them first. Don’t just assume they’re fine.
- Look at the full med list. Is the patient on a diuretic? An SSRI? A calcium channel blocker? A Class Ia or III antiarrhythmic? Each one adds up.
For patients with two or more risk factors, consider alternatives. If you’re treating community-acquired pneumonia, doxycycline or a cephalosporin might be just as effective.
There’s also a simple scoring tool-the QT Risk Score from the University of Arizona. It assigns points for each risk factor. A score of 7 or higher means high risk. Avoid macrolides entirely in those cases.
Real-World Impact: What Hospitals Are Doing
Some health systems have already acted. Kaiser Permanente, which serves over 12 million people, added a pop-up alert in their EHR system in 2017. If a doctor tried to prescribe azithromycin or clarithromycin to a patient with a QTc >500 ms or on three or more QT-prolonging drugs, the system blocked the prescription unless overridden. Result? A 28% drop in high-risk prescriptions.
Meanwhile, clarithromycin use in cardiac patients has dropped 34% since 2013. Azithromycin use hasn’t changed much-partly because many still believe it’s safer. But that belief is outdated.
The Future: Safer Antibiotics?
Solithromycin, a newer ketolide, showed no QT prolongation in clinical trials. It was designed to avoid the IKr blockade that causes the problem. But the FDA rejected it in 2016 because of liver toxicity. That’s the trade-off: fix one safety issue, and another pops up.
Right now, there’s no magic bullet. The best tool we have is awareness. And careful prescribing.
What Patients Should Know
If you’re prescribed a macrolide and you have heart disease, take diuretics, or are over 65, ask: "Is there another antibiotic I could take?" Don’t assume azithromycin is "safe." It’s safer than clarithromycin-but not risk-free.
Also, if you’re on multiple medications, bring your full list to your doctor. Many QT-prolonging drugs are common: antidepressants, antifungals, anti-nausea meds, even some heartburn pills. They add up.
If you feel dizzy, lightheaded, or have palpitations after starting the antibiotic, stop it and call your doctor. Don’t wait. TdP can strike quickly.
Do all macrolides carry the same risk of arrhythmia?
No. Clarithromycin has the highest risk, followed by erythromycin. Azithromycin carries a lower but still present risk. Clarithromycin is a stronger blocker of the IKr potassium channel and also interferes with liver enzymes that break down other QT-prolonging drugs. Azithromycin doesn’t affect those enzymes, which is why it’s often chosen over the others-but it still prolongs the QT interval, especially in high-risk patients.
Can azithromycin cause sudden cardiac death?
Yes, but it’s rare. The absolute risk is very low in healthy people. However, in patients with multiple risk factors-like older age, heart disease, low potassium, or taking other QT-prolonging drugs-the risk increases significantly. A 2012 study found 152 excess cardiovascular deaths per million courses of azithromycin. That’s not common, but it’s preventable with better screening.
Should I get an ECG before taking a macrolide?
If you have any of the seven major risk factors (female sex, age over 65, heart disease, low potassium, kidney problems, genetic long QT, or taking other QT-prolonging drugs), yes. A baseline ECG to check your QTc interval is simple, cheap, and can prevent a life-threatening event. For healthy young adults with no other meds or conditions, it’s usually not needed.
Are there safer antibiotics for people with heart conditions?
Yes. For many infections, doxycycline, amoxicillin, or cephalexin are just as effective and carry no known QT risk. Fluoroquinolones like levofloxacin also prolong QT, so they’re not always safer. The best choice depends on the infection type and patient history. Always ask your doctor if there’s a non-QT-prolonging alternative.
Why is clarithromycin more dangerous than azithromycin?
Clarithromycin blocks the IKr potassium channel more strongly than azithromycin, leading to greater QT prolongation. It also inhibits the CYP3A4 enzyme, which can raise levels of other QT-prolonging drugs like statins or antiarrhythmics. Azithromycin doesn’t inhibit this enzyme, so it has fewer dangerous interactions. But both can still cause arrhythmias in high-risk patients.
How common is Torsades de Pointes from macrolides?
The estimated incidence is 3-7 cases per million treatment courses. In the U.S., the FDA’s adverse event database recorded 287 cases of TdP linked to macrolides between 2010 and 2020. Most occurred in patients with multiple risk factors. While rare, these events are often fatal-making prevention critical.